Results 31 to 40 of about 7,229 (203)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

Viruses, 2023
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and ...
Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Chiara Molteni, Addolorata Masiello, Giancarlo Orofino, Barbara Menzaghi, Rita Bellagamba, Francesca Vichi, Benedetto Maurizio Celesia, Giordano Madeddu, Giovanni Francesco Pellicanò, Maria Aurora Carleo, Antonio Cascio, Andrea Parisini, Lucia Taramasso, Laura Valsecchi, Leonardo Calza, Stefano Rusconi, Eleonora Sarchi, Salvatore Martini, Olivia Bargiacchi, Katia Falasca, Giovanni Cenderello, Sergio Ferrara, Antonio Di Biagio, Paolo Bonfanti   +28 more
doaj   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

British Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno, Berta Torres, Maria Martínez‐Rebollar, Paula Arreba, Octavi Roman, Roger LLobet, Leire Berrocal, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Ivan Chivite, Elisa de Lazzari, Josep Mallolas, Ana González‐Cordón   +13 more
wiley   +1 more source

Number of patients susceptible to etravirine and rilpivirine.

, 2016
Number of patients susceptible to etravirine and rilpivirine.
Anchalee Avihingsanon (340691), Kiat Ruxrungtham (247724), Opass Putcharoen (2633791), Suwanna Mekprasan (2633794), Phairote Teeranaipong (2633797), Pirapon June Ohata (2633788), Sunee Sirivichayakul (7870)   +6 more
core   +1 more source

DataSheet1_Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.docx

, 2022
Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy.
Sandra Grañana-Castillo (12013841), Rachel Bearon (14262146), Saye Khoo (575924), Marco Siccardi (1518958), Maiara Camotti Montanha (12013826)   +4 more
core   +1 more source

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells

Pharmaceuticals, 2022
The global burden of cancer necessitates rapid and ongoing development of effective cancer therapies. One promising approach in this context is the repurposing of existing non-cancer drugs for cancer indications.
Saiful Islam, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H. Martin, Shudong Wang, Richard Head   +6 more
doaj   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

PLoS Pathogens, 2015
Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs.
Martina Kovarova, Olivia D Council, Abhijit A Date, Julie M Long, Tomonori Nochi, Michael Belshan, Annemarie Shibata, Heather Vincent, Caroline E Baker, William O Thayer, Guenter Kraus, Sophie Lachaud-Durand, Peter Williams, Christopher J Destache, J Victor Garcia   +14 more
doaj   +1 more source

Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR

Future Journal of Pharmaceutical Sciences, 2021
Background Using a Symmetry C18 (4.6 × 150 mm, 3.5) column, a high-performance liquid chromatographic method for quantification of Rilpivirine and Cabotegravir in active pharmaceutical ingredients was developed and validated.
Anuradha Vejendla, Subrahmanyam Talari, Raju Moturu, S. N. Murthy Boddapati, A. Emmanuel Kola   +4 more
doaj   +1 more source

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine [PDF]

, 2015
This is an open access article under the CC BY-NC-ND license - http://creativecommons.org/licenses/by-nc-nd/4.0/"Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its ...
Gomes, P., Rhee, S. Y., on behalf of the Portuguese HIV-1 Resistance Study Group, Camacho, R. J., Theys, K., Vandamme, A. M.   +5 more
core   +3 more sources

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source